Combination chemotherapy in murine neuroblastoma
โ Scribed by Finklestein, J. Z. ;Tittle, K. ;Rubenstein, J. ;Meshnik, R. ;Weiner, J.
- Publisher
- John Wiley and Sons
- Year
- 1976
- Tongue
- English
- Weight
- 539 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
The C1300 murine neuroblastoma system has been studied to determine its relevance as a chemotherapy model to the human disease. Studies using combination therapy revealed that BCNU/cyclophosphamide combination therapy increased the median lifespan 300% in A/J mice bearing the C1300 tumor. Cyclophosphamide/imidazole carboxamide and adriamycin/imidazole carboxamide combinations were less active, increasing median lifespans 189% and 144%, respectively. Vincristine/bleomycin were inactive even when the schedule was adjusted to coincide with the time of maximum mitoses following vincristine injections. These results suggest the BCNU/cyclophosphamide combination chemotherapy may be effective in human disease.
๐ SIMILAR VOLUMES
A retrospective analysis of 46 histologically proven cases of neuroblastoma is presented. The over-all 2-year survival was 46%. All except 1 of the 21 patients surviving 2 years were continuously free of clinical and laboratory evidence of neuroblastoma. The patients treated before 1967 were treated
Single a n d combination chemotherapy was evaluated for antitumor activity against N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT)-induced bladder carcinoma in syngeneic mice.